Subscribe to RSS
DOI: 10.1055/a-2331-2300
Discontinuation Rate of Lurasidone and Quetiapine Extended Release in Bipolar Depression
Funding This study was supported by JSPS KAKENHI (grant number 23K06998).
Abstract
Introduction Lurasidone (LUR) was compared with quetiapine extended release (QUE-ER) regarding 1-year discontinuation in patients with bipolar depression (n=317).
Methods This is a retrospective cohort study.
Results Although the time to all-cause discontinuation was estimated using the Kaplan–Meier survival curve with log-rank tests to compare treatment groups, no difference was found (p=0.317). The Cox proportional hazard model revealed that only the presence of adverse events (AEs) is associated with increased treatment discontinuation (p<0.0001). The most common AEs were akathisia for LUR (17.7%) and somnolence for QUE-ER (34.7%). In other Cox models divided by LUR or QUE-ER, the presence of akathisia or somnolence was associated with increased LUR (p=0.0205) or QUE-ER (p<0.0001) discontinuation, respectively.
Discussion The acceptability of both antipsychotics to bipolar depression in clinical practice may be similar. However, specific AEs for each antipsychotic (LUR: akathisia and QUE-ER: somnolence) were associated with high treatment discontinuation.
Publication History
Received: 06 March 2024
Received: 11 April 2024
Accepted: 13 May 2024
Article published online:
19 June 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Nierenberg AA, Agustini B, Kohler-Forsberg O. et al. Diagnosis and treatment of bipolar disorder: A Review. JAMA 2023; 330: 1370-1380
- 2 Kishi T, Ikuta T, Matsuda Y. et al. Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: A systematic review and network meta-analysis of randomized controlled trials. Mol Psychiatry 2021; 26: 4146-4157
- 3 Kishi T, Sakuma K, Okuya M. et al. Effects of a conventional mood stabilizer alone or in combination with second-generation antipsychotics on recurrence rate and discontinuation rate in bipolar I disorder in the maintenance phase: A systematic review and meta-analysis of randomized, placebo-controlled trials. Bipolar Disord 2021; 23: 789-800
- 4 Lieberman JA, Stroup TS, McEvoy JP. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223
- 5 Kishi T, Ikuta T, Matsuda Y. et al. Pharmacological treatment for bipolar mania: A systematic review and network meta-analysis of double-blind randomized controlled trials. Mol Psychiatry 2022; 27: 1136-1144
- 6 Yildiz A, Siafis S, Mavridis D. et al. Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: A systematic review and network meta-analysis. Lancet Psychiatry 2023; 10: 693-705
- 7 APA. Diagnostic and statistical manual of mental disorders, 5th ed. American Psychiatric Association; Arlington: 2013
- 8 Zhang Z. Variable selection with stepwise and best subset approaches. Ann Transl Med 2016; 4: 136
- 9 Wu H, Siafis S, Wang D. et al. Antipsychotic-induced akathisia in adults with acute schizophrenia: A systematic review and dose-response meta-analysis. Eur Neuropsychopharmacol 2023; 72: 40-49
- 10 Li Q, Wang J, Wang ZL. et al. The impacts of CYP3A4 genetic polymorphism and drug interactions on the metabolism of lurasidone. Biomed Pharmacother 2023; 168: 115833
- 11 Lin SK. Racial/ethnic differences in the pharmacokinetics of antipsychotics: focusing on East Asians. J Pers Med 2022; 12
- 12 Kato T, Ishigooka J, Miyajima M. et al. Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression. Psychiatry Clin Neurosci 2020; 74: 635-644
- 13 Murasaki M, Koyama T, Kanba S. et al. Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression. Psychopharmacology (Berl) 2018; 235: 2859-2869